SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056918
Filing Date
2024-05-09
Accepted
2024-05-09 16:08:10
Documents
77
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kzr-20240331.htm   iXBRL 10-Q 1811152
2 EX-31.1 kzr-ex31_1.htm EX-31.1 15956
3 EX-31.2 kzr-ex31_2.htm EX-31.2 15921
4 EX-32.1 kzr-ex32_1.htm EX-32.1 9594
5 GRAPHIC img40156747_0.jpg GRAPHIC 81338
  Complete submission text file 0000950170-24-056918.txt   8349790

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20240331.xsd EX-101.SCH 1183977
80 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20240331_htm.xml XML 1435653
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38542 | Film No.: 24930556
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)